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Abstract
Purpose – While research has consistently identified an association between cannabis use and psychosis,
few studies have examined this relationship in a polydrug context (i.e. combining cannabis with other illicit
substances). The paper aims to discuss this issue.
Design/methodology/approach – The present study sought to examine the association between
recreational drug use (cannabis only vs polydrug) and psychotic disorders. Analysis was conducted on a
large, representative survey of young Danish people aged 24 (n¼4,718). Participants completed self-report
measures of lifetime drug use and this information was linked to the Danish psychiatric registry system.
Findings – Multivariate binary logistic regression analysis was used to examine the association between
drug use (no drug use, cannabis only, cannabis and other drug) and ICD-10 psychotic disorders,
while controlling for gender and parental history of psychosis. Compared with no drug use, the use of
cannabis only did not increase the risk of psychosis while the odds ratio for cannabis and other drug were
statistically significant.
Research limitations/implications – Psychosis risk may be associated with the cumulative effect
of polydrug use.
Practical implications – Cannabis use may be a proxy for other drug use in research studies.
Originality/value – This study is innovative as it uses linked self-report and administrative data for a large
sample. Administrative data were used to as an objective mental health status indicator.
Keywords Logistic regression, Psychosis, Cannabis, Data linkage, Polydrug use, Registry data
Paper type Research paper
Introduction
An association between cannabis use and psychosis has been well-documented in the
epidemiological literature (Gage et al., 2016). Indeed, a recent meta-analysis found evidence of a
dose-response relationship, in which the heaviest users (in terms of both frequency and strength
of substance consumed) were almost four times as likely to experience clinical-level psychotic
outcomes compared with non-users (Marconi et al., 2016). Despite such findings, the potential
causal role of cannabis use in the development of psychosis continues to be debated. There are
a number of methodological challenges that impede the investigation of this association
(Ksir and Hart, 2016). In the absence of experimental studies, it is difficult to isolate the unique effect
(if any) that cannabis consumption has on psychosis (Ksir and Hart, 2016). With regards to
epidemiological evidence, it is worth noting that while an association has consistently been reported,
cannabis is the most the most commonly used recreational drug worldwide (Morley et al., 2015;
National Institutes of Health, 2015; Haberstick et al., 2014; Degenhardt et al., 2013), and it is
associated with many other well-documented risk factors for psychosis (Ksir and Hart, 2016) such
as a pre-existing vulnerability to psychosis (Power et al., 2014). In their review of the extant literature,
and paying attention to the Bradford Hill (1965) criteria for inferring causality from epidemiological
data, Ksir and Hart (2016, p. 11) concluded that cannabis use in itself was not a definitive causal
factor for psychosis, rather that “[…] early use and heavy use of cannabis aremore likely in individuals
with a vulnerability to psychosis”.
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One methodological challenge that has received relatively little interest in the literature is the issue of
polydrug use. Cannabis use is the most commonly used drug within a polydrug context; studies of
typologies of polydrug use have observed high levels of cannabis use across a range of groups that
differ both qualitatively (in terms of the types of substances consumed) and quantitatively
(in terms of their class counts, and associations with physical and mental health outcomes)
(Stefanis et al., 2014; Smith et al., 2011; Fergusson et al., 2006; Lynskey et al., 2006; Carlson et al.,
2005;Mitchell and Plunkett, 2000). While there have beenmany plausible hypotheses to explain the
biological mechanisms that link cannabis use and psychosis (Solowij et al., 2013; Bhattacharyya
et al., 2009; Rais et al., 2008; Szeszko et al., 2007; Linszen and van Amelsvoort, 2007;
D’Souza et al., 2000) research suggests that psychosis is also related to the use of other illicit
drugs. For example, stimulants (Sara et al., 2014; Medhus et al., 2015) and hallucinogens
(Marona-Lewicka et al., 2011) have also been identified as risk factors for the development of
psychotic disorders/experiences. As cannabis use frequently co-occurs with the use of other drugs
that have been shown to be associated with psychosis risk, and given that cannabis is the most
widely used recreational drug, it is possible that the unique deleterious effect of cannabis use may
have been overstated in previous research.
Despite the fact that cannabis and other illicit substances are frequently used together, the
association between cannabis use and psychosis has rarely been studied in a polydrug context.
While a number of studies have found associations between cannabis use and psychosis, even after
controlling for the presence of other drugs, the findings have been somewhat inconsistent and there
were significant methodological differences between these studies. van Os et al. (2002) examined
the association between self-reported cannabis use and any psychotic disorder in general
population (n¼ 4,045) and clinical (n¼ 59) samples followed over a three year period. A strong,
effect of cannabis use on later psychotic disorder was observed, and was not attenuated when
other drug use was included in the model. Henquet et al. (2006) examined the relation between
cannabis use and psychotic symptoms in individuals with above average predisposition for
psychosis who first used cannabis during adolescence (n¼ 2,437). The inclusion of other drug use
and predisposition to psychosis led to an attenuated effect, with the adjusted point estimate
moderate in strength (OR¼ 1.67). Arguably the most comprehensive study which controlled for
other drug use was conducted by Zammit et al. (2002). Using Swedish conscript data (n¼ 50,087)
they examined the association between self-reported cannabis and other drug use and later
psychiatric admissions, assessed using data linkage. Overall, cannabis use had a dose-response
association with psychotic diagnosis, even in those who reported using only cannabis, however the
inclusion of other drugs led to attenuated effects. Gage et al. (2014) examined the association
between cannabis use and subsequent psychotic experiences (PLEs) in a cohort of adolescents
(n¼ 1,756). They found that, when the confounding effects of tobacco, alcohol, and other drugs
were controlled for, the effect of cannabis use on PLE dropped to a relatively minor level (OR¼ 1.25).
The majority of studies that have examined the cannabis-psychosis association have treated
other drug use as a covariate. Fewer studies have explicitly examined the impact of combining
cannabis with other substances on the subsequent development of psychosis. Studies that have
taken this approach have found that such a combination resulted in considerably higher levels of
risk compared with cannabis use alone. For example, Van Dam et al. (2008) examined
schizotypal symptoms in users of both legal and illicit substances (n¼ 328). Participants were
divided into three groups based on their drug use patterns; legal drug only, cannabis and legal
drug, cannabis polydrug. Those in the legal drug and cannabis-legal drug groups did not differ
significantly on self-reported schizotypy, whereas those in the polydrug group scored significantly
higher. Similarly, in a community cohort followed over 30 years (n¼ 591), Rössler et al. (2012)
found considerably stronger associations between “multiple-drug use” (i.e. cannabis plus at least
one other drug) and psychotic experiences, compared with the use of cannabis alone. This effect
was particularly strong when the analyses focussed on “schizophrenia nuclear symptoms”
suggesting that polydrug use may be a risk for more severe, clinical levels of psychosis. Given that
these studies have focussed primarily on self-reported psychotic-like experiences, further
research is required exploring the impact of polydrug use on clinical psychosis.
The main aim of this study was to assess the association between patterns of recreational drug
use (no drug use, cannabis only, cannabis and other drug) and psychotic disorders. Data from a
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large interview survey based on a stratified random probability sample of young Danish people
aged 24 years was used to assess life-time drug use and this information was linked to the Danish
psychiatric registry for identification of participants who had a life-time ICD-10 diagnosis of a
psychotic disorder and also to control for parental psychotic disorder. It was predicted that
cannabis use and polydrug use would both be significantly associated with a diagnosis of a
psychotic disorder while controlling for parental psychosis. It was expected that the effect size
would be larger for polydrug use compared to cannabis only.
Method
Participants and procedures
Information on drug use was collected as part of a Danish national study conducted by
The Danish National Centre for Social Research between 2008 and 2009. The aim of this study
was to gather mental health-related data from young Danish people. A stratified random
probability sample (n¼ 4,718) drawn from the entire birth cohort of Danes born in 1984
(participants aged 24 years) were contacted (participants aged 24 years and 2,980 individuals
agreed to be interviewed. The response rate was 63 per cent. Participation in the interview was
voluntary and the study was approved by the Danish Data Protection Agency. To increase the
number of participants, who had been victims of childhood abuse and neglect, children who had
been in child protection, were over-sampled by a ratio of 1:2 of “child protection cases” vs
“non-child protection cases”. A child protection case was defined as a case when the local
authority (according to the files of local social workers) had provided support for the child and the
family or placement with a foster family due to concerns about the well-being and development of
the child. A total of 852 interviews were conducted with individuals who had been previously
identified by the Danish authorities as child protection cases. To account for the oversampling of
child protection cases and to ensure findings were representative of the total Danish population of
young people aged 24, the data were analysed using a weight variable with a weighted child
protection status of 6.3% of the total sample. A structured interview was conducted by
telephone, or by residential visit if telephone contact could not be made (mean duration of
interview was 43 minutes). All individuals who volunteered to take part in the interview received
written contact prior to the interview informing them of the process of the interview, the nature of
the questions to be asked, and the process of confidentiality. All interviewers were formally
trained and instructed by The Danish National Centre for Social Research and participated in test
trials to become familiar with the questionnaire and the coding procedures.
The survey responses were linked to data from the Danish Civil Registration System and the
Danish Psychiatric Central Register. A detailed description of the structure of CRS was provided
by Pedersen et al. (2006). Access to the CRS was provided by Denmark Statbank upon
completion of a research proposal. The relevant variables requested are matched to individuals
using the person’s civil registry number (CPR). The CPR identifies people at the individual level
and allows information to be collated across different registries.
Measures
The survey included a section on drug use. Participants were asked “Have you ever tried[…]” and
the following drugs were listed: amphetamine (Speed), cannabis (hashish/pot), cocaine (coke/
crack), LSD (acid), mushrooms with narcotic effect, heroin, solvents (sniffing), other (ecstasy).
Each drug was scored “Yes” (1) or “No” (0). The scores were recoded into a categorical variable
that represented: no drug use, cannabis only, and cannabis and any other drug.
The outcome variable was a diagnosis of psychotic disorder recorded between the years 1984
and 2005 (approximating an age range from birth to 21 years). Every time a person has contact
with a psychiatric hospital or department in Denmark they receive an ICD-10 (previously ICD-8/9)
diagnosis code that is recorded on the Psychiatric Central Register. The diagnosis is made by a
psychiatrist. For this study we used information from the Psychiatric Central Register to identify
which participants had received a diagnosis of any psychotic disorder (ICD-10 F20-F29; ICD8/9
295, 298.09, 298.19, 298.29, 298.39, 298.89, 297, 298.99, 299). These data are available as
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part of the Danish Civil Registration System (CRS) and the Danish Psychiatric Central Register.
Parental data for all was also available from four years prior to birth (1980) to 2005; parental
psychosis was indicated if either parent had a ICD-10 (F20-F29) diagnosis during this time period.
Analysis
χ2 tests were used to examine the bivariate associations between the predictor and outcome
variables. Binary logistic regression analysis was used to examine the association between drug use
category and psychotic disorder. Analyseswere conducted using SPSS version 21 (IBMCorp., 2012).
Results
Slightly more than half of the sample were male (52.2 per cent), 14 (0.5 per cent) had received a
diagnosis of a psychotic disorder, and there were 45 (1.5 per cent) cases of parental diagnosis
of psychosis. Almost half of the participants reported no drug use (48.4 per cent), a further
31.6 per cent reported using cannabis only and 20.0 per cent reported using cannabis and any
other drug. The bivariate associations between the psychosis diagnosis and other variables are
reported in Table I.
Table I shows that there was no association between psychosis diagnosis and gender or parental
psychosis. There was a significant association between psychosis diagnosis and drug use with more
participants with a diagnosis having reported using cannabis and other drug(s). The variables were
entered into a binary logistic regression with the psychosis diagnosis as the dependent variable.
Gender, parental psychosis and drug use were entered as predictors with the “No drug” category
used as the reference level. The model was statistically significant ( χ2¼ 13.68, df¼ 4, po0.05;
Cox and Snell R2¼ 0.004; Nagelkerke R2¼ 0.07). The results in Table II show that, compared to the
no drug use group, cannabis use only did not increase the risk of psychosis while the odds ratio for
was cannabis and other drug were statistically significant (OR¼ 5.96).
In order to determine which drugs in combination with cannabis were contributing to this effect a
series of χ2 analyses were conducted. The drug use data were recoded into seven binary
variables to represent the use of: amphetamine with cannabis; cocaine with cannabis; LSD with
cannabis; mushrooms with cannabis; heroin with cannabis; solvents with cannabis; and other
Table I Cross-tabulation of psychosis diagnosis, gender, parental psychosis and drug use
Psychosis diagnosis count (%)
No (n¼2,964) Yes (n¼14) χ2 (df ) p
Gender (Male) 1,546 (52.2%) 7 (50.0%) 0.03 (1) 0.87
Parental psychosis 45 (1.5%) 0 (0%) 0.22 (1) 0.64
Drug use
No drug use 1,437 (48.5%) 4 (28.6%)
Cannabis only 940 (31.7%) 2 (14.3%)
Cannabis and other drug 586 (19.8%) 8 (57.1%) 12.23 (2) po0.01
Table II Binary logistic regression for psychosis diagnosis, gender, parental psychosis and
drug use
B Sig. OR 95% CI
Gender (Male) −0.56 0.32 0.57 (0.19-1.72)
Parental Psychosis 0.64 0.68 1.90 (0.09-39.81)
No drug use (reference category)
Cannabis only −0.37 0.68 0.69 (0.12-4.07)
Cannabis and other drug 1.79 0.01 5.96 (1.71-20.75)
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drug with cannabis. χ2 tests were used to test the association between these variables and
psychosis diagnosis. The chi-square tests were significant for amphetamine with cannabis
( χ2¼ 6.30, df¼ 1, po0.05; OR¼ 3.71 95% CI 1.24-11.14), cocaine with cannabis ( χ2¼ 12.96,
df¼ 1, po0.01; OR¼ 5.66 95% CI 1.95-16.42), mushrooms with cannabis ( χ2¼ 20.00, df¼ 1,
po0.01; OR¼ 8.26 95% CI 2.74-24.89), and solvents with cannabis ( χ2¼ 10.57, df¼ 1,
po0.01; OR¼ 5.15 95% CI 1.71-15.46). Finally, to examine the effect of the number of different
drugs used a variable that was computed that represented the total number of different drugs
used, ranging from 0 (no drug use) to 7 (all drugs). This variable was entered as a predictor in a
binary logistic regression with psychosis as the dependent variable. The model was statistically
significant ( χ2¼ 7.20, df¼ 1, po0.01) and the odds ratio for the number of different drugs used
was 1.38 (95% CI 1.11-1.68). This indicates that each additional drug that is used increases the
likelihood of a diagnosis of psychosis.
Discussion
The main aim of this study was to assess the association between patterns of recreational drug
use (no drug use, cannabis only, cannabis and other drug) and psychotic disorders. It was
predicted that cannabis use alone and polydrug use would both be significantly associated with a
diagnosis of a psychotic disorder while controlling for parental psychosis. It was also expected
that the effect size would be larger for polydrug use compared to cannabis only. The results
partially supported the hypotheses. Although there was a significant bivariate association
between psychosis diagnosis and drug use, with more participants with a diagnosis having
reported using cannabis and other drugs, the logistic regression showed that there was no
significant effect for cannabis only. Only polydrug use was significantly related to psychosis, with
the odds increasing by almost six times compared to the “no drug” group. Follow-up analyses
showed that different combinations of cannabis and other drugs were associated with psychosis;
cannabis in combination with amphetamine, cocaine, mushrooms and solvents were all
significantly associated with psychosis. There was also a significant dose-response relationship
for the number of different drugs used and psychosis.
Although a large number of previous studies have examined the relationship between cannabis
use and subsequent psychosis, the use of other drugs has largely been reduced to covariate
status (e.g. Gage et al., 2014; Henquet et al., 2006; van Os et al., 2002; Zammit et al., 2002).
Studies that have controlled for the presence of other drugs have delivered equivocal results, with
some reporting moderate-to-strong associations between cannabis use and subsequent
psychosis (van Os et al., 2002; Zammit et al., 2002; Henquet et al., 2006), while others have
reported greatly attenuated effects (Gage et al., 2014). Studies that have tested specific
permutations of polydrug use have suggested that the combination of cannabis with other
substances leads to markedly increased risk for psychosis. Van Dam et al. (2008), found those
who used legal drugs alone and those who combined legal drugs with cannabis did not differ
significantly on a self-report measure of schizotypy, while those who combined cannabis with
other illegal drugs scored significantly higher. Similarly, Rössler et al. (2012) examined data from a
Swedish cohort followed over a thirty year period and found that polydrug users had a
significantly greater risk of developing psychotic experiences compared with those who used
cannabis alone. Both of these studies used sub-clinical measures of psychosis. The present
study adds to the literature by demonstrating a similar association when a clinical diagnosis of
psychotic disorder is used as the primary outcome measure. This provides indirect evidence for
the “psychosis continuum” (Strauss, 1969; van Os et al., 2000) as it suggests that risk factors for
psychosis operate in a consistent manner at both clinical and sub-clinical levels of psychosis.
The findings of the present study indicate that, when patterns of cannabis and polydrug use are
examined in greater detail, the unique effect of cannabis consumption is greatly attenuated.
As such, the effect of cannabis use on the development of psychosis may have been overstated
in previous studies which failed to control for confounding effects of other drugs. One explanation
for the consistent findings of an association between cannabis and psychosis is that cannabis
use is a proxy for other drug use, and it may be that other drugs represent the true risk factor.
Indeed, in the present study the number of different drugs used was associated with psychosis in
a “dose-response” fashion. However, there does not appear to be specificity as different drugs
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have been shown to be associated with increased risk of psychosis or psychotic-like
experiences; methamphetamine (McKetin et al., 2010), cocaine (Thirthalli and Benegal, 2006),
and psychedelics (Kuzenko et al., 2011). The present findings highlight the importance of
considering cannabis use within a broader polydrug context when attempting to infer causal links
with psychosis. There are also clinical implications associated with these findings. It would be
preemptive to state that smoking cannabis is a benign activity in relation to mental health, as
much more research is required. In addition, the negative social, cognitive and physical
consequences of cannabis use have been well documented (see review by Hall, 2015).
Although cannabis use may be a proxy indicator for other forms of drug use, it is also likely to be
associated (or interact) with other risk factors for psychosis such as childhood trauma (Houston et al.,
2011), familial risk for psychosis (Giordano et al., 2014), ethnicity and social disadvantage (Morgan
et al., 2009). Therefore, future studies of the effects of cannabis should place cannabis use within a
broader context of correlated risk-factors, such as the social defeat model (Selten et al., 2013).
Although it may be difficult to isolate the unique effect of cannabis use on psychosis using
epidemiological methods, alternative methods may be of use. Up until very recently, experimental
studies using human subjects were all but impossible given the legal status of cannabis. Although
animal studies offer some insight, there is no reliable model of psychosis in animals, making the
generalisation of findings difficult (Murray and DiForti, 2016). Following the legalisation of
recreational marijuana in various parts of the USA in 2016, there will be increasing opportunities to
test for causal associations between cannabis use and psychosis. This presents an opportunity
to test different aspects of cannabis use that have been implicated in the “dose-response”
relationship, e.g. frequency, type and strength (Marconi et al., 2016).
The findings of the present study should be considered in light of the following limitations. First, drug
use was assessed using retrospective self-reports, which are open to under-or over-reporting.
Second, the temporal ordering of drug use and diagnosis of psychosis cannot be established.
Third, participant information about the frequency, type or strength of cannabis use was not
available, meaning the dose-response nature of the cannabis-psychosis association could not be
examined. Fourth, information regarding psychotic diagnosis was only available up until age 21, yet
it is relatively common for psychosis to emerge up to the age of 35 years (Kessler et al., 2007).
As such, the lifetime prevalence rate for psychotic disorder was relatively low in the present sample.
Further research over a greater age range is recommended. Fifth, the genetic risk for psychosis was
only approximated by using data for parental diagnosis of psychosis. Data were limited to a
recorded diagnosis anytime from four years prior to the birth of the study child until the child was
assessed aged 21, likely leading to an underestimation of parental psychosis. Finally, the cell counts
for the psychosis variable are very unbalanced, with a small number of psychosis cases. This can
cause problems with the estimation of the logistic model. The effects of “rare event” outcomes have
been shown to produce bias in the estimates by underestimating the probability of the outcome
variable (King and Zeng, 2001). The non-significant effect for the “Cannabis only” category of
the drug use variable should be interpreted in light of the potential of a Type 2 error occurring.
In summary, this study aimed to assess the relationship between patterns of recreational drug
use (no drug use, cannabis only, cannabis and other drug) and psychotic disorders. There was
no significant effect for cannabis alone, but cannabis in conjunction with other drugs was
statistically significant. Follow-up analyses indicated that polydrug use was significantly
associated with increased risk of psychosis. Future research should address the context of
cannabis use, both as part of more complex patterns of drug use but also in the context of a
broader set of social, economic, and psychological risk factors.
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